EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

$8.81 -0.40 (-4.34%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$8.81 0.00 (0.00%)

As of 03:59 AM Eastern

EyePoint Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 9 Analyst Ratings

Sell
0

Hold
0

Buy
9

Based on 9 Wall Street analysts who have issued ratings for EyePoint Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 9 have given a buy rating for EYPT.

Consensus Price Target

$25.38
188.02% Upside

According to the 9 analysts' twelve-month price targets for EyePoint Pharmaceuticals, the average price target is $25.38. The highest price target for EYPT is $33.00, while the lowest price target for EYPT is $15.00. The average price target represents a forecasted upside of 188.02% from the current price of $8.81.

Get the Latest News and Ratings for EYPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for EyePoint Pharmaceuticals and its competitors.

EYPT Analyst Ratings Over Time

Type	Current Forecast 6/12/24 to 6/12/25	1 Month Ago 5/13/24 to 5/13/25	3 Months Ago 3/14/24 to 3/14/25	1 Year Ago 6/13/23 to 6/12/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.38	$25.29	$26.63	$33.29
Forecasted Upside	188.02% Upside	327.85% Upside	308.36% Upside	257.14% Upside
Consensus Rating	Buy	Buy	Buy	Buy

EYPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EYPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

EyePoint Pharmaceuticals Stock vs. The Competition

Type	EyePoint Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	188.02% Upside	5,924.54% Upside	13.15% Upside
News Sentiment Rating	Positive News See Recent EYPT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/29/2025	HC Wainwright 1 of 5 stars	Yi Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00	+212.28%
5/16/2025	Mizuho 3 of 5 stars	Graig Suvannavejh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$30.00 ➝ $26.00	+338.45%
5/8/2025	Chardan Capital 1 of 5 stars	Daniil Gataulin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$33.00 ➝ $27.00	+343.35%
1/7/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$33.00	+280.18%
11/11/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$38.00 ➝ $33.00	+183.75%
10/16/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$18.00	+82.19%
8/28/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$15.00	+65.02%
8/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$32.00 ➝ $29.00	+246.89%
6/20/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
2/16/2024	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chiang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
Get the Latest News and Ratings for EYPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:37 AM ET.

Should I Buy EyePoint Pharmaceuticals Stock? EYPT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, June 12, 2025. Please send any questions or comments about these EyePoint Pharmaceuticals pros and cons to contact@marketbeat.com.

EyePoint Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in EyePoint Pharmaceuticals, Inc.:

EyePoint Pharmaceuticals, Inc. has a promising product pipeline, particularly with EYP-1901, which is in Phase 2 clinical trials for treating serious retinal diseases such as wet age-related macular degeneration, non-proliferative diabetic retinopathy, and diabetic macular edema. Successful outcomes could lead to significant market opportunities.
The company reported revenue of $24.50 million in the latest quarter, significantly exceeding analyst estimates of $8.84 million, indicating strong market demand and operational performance.
Analysts have a generally positive outlook on the stock, with an average rating of "Moderate Buy" and a target price of $25.38, suggesting potential for price appreciation.
EyePoint Pharmaceuticals, Inc. utilizes proprietary Durasert E technology for sustained drug delivery, which could provide a competitive edge in the biopharmaceutical market.
The current stock price is positioned at a level that may attract investors looking for growth opportunities in the biopharmaceutical sector, especially given the company's innovative approach to treating retinal diseases.

EyePoint Pharmaceuticals
Bear Case

Investors should be bearish about investing in EyePoint Pharmaceuticals, Inc. for these reasons:

The company has a negative net margin of 226.57%, indicating that it is currently spending significantly more than it earns, which could raise concerns about financial sustainability.
EyePoint Pharmaceuticals, Inc. reported a negative return on equity of 43.01%, suggesting that the company is not generating sufficient profit relative to shareholder equity, which may deter potential investors.
Despite the positive revenue report, the company is still in the clinical stage, meaning that there is inherent risk associated with the success of its product candidates and their eventual market approval.
One investment analyst has rated the stock with a sell rating, which could indicate potential risks or concerns that may not be fully addressed by the broader analyst community.
Market volatility and competition in the biopharmaceutical sector could impact the company's growth prospects and stock performance, making it a riskier investment choice.

EYPT Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for EyePoint Pharmaceuticals is $25.38, with a high forecast of $33.00 and a low forecast of $15.00.
: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares.
: According to analysts, EyePoint Pharmaceuticals's stock has a predicted upside of 188.02% based on their 12-month stock forecasts.
: EyePoint Pharmaceuticals has been rated by research analysts at Chardan Capital, HC Wainwright, and Mizuho in the past 90 days.
: Analysts like EyePoint Pharmaceuticals more than other "medical" companies. The consensus rating for EyePoint Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EYPT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:EYPT) was last updated on 6/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target